Combination of uric acid and NT-proBNP: A more useful prognostic marker for short-term clinical outcomes in patients with acute heart failure

Korean Journal of Internal Medicine

Volumn 25, Issue 3, 2010, Pages 253-259

  Park, Hyoung Seob ^a   Kim, Hyungseop ^a   Sohn, Ji Hyun ^a   Shin, Hong Won ^a   Cho, Yun Kyeong ^a   Yoon, Hyuck Jun ^a   Nam, Chang Wook ^a   Hur, Seung Ho ^a   Kim, Yoon Nyun ^a   Kim, Kwon Bae ^a   Park, Hee Joon ^a  

^a Keimyung University School of Medicine   (South Korea)

Author keywords

Heart failure; Natriuretic peptides; Uric acid

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; URIC ACID; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE HEART FAILURE; AGED; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; FOLLOW UP; HEART DEATH; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN BLOOD LEVEL; SENESCENCE; URIC ACID BLOOD LEVEL; BLOOD; HEART FAILURE; KAPLAN MEIER METHOD; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; TREATMENT OUTCOME; URIC ACID;

EID: 77957023579     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2010.25.3.253     Document Type: Article

References (26)

1. Lainchbury JG, Campbell E, Frampton CM, et al. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003;42:728-735.
2. Song BG, Jeon ES, Kim YH, et al. Correlation between levels of Nterminal pro-B-type natriuretic peptide and degrees of heart failure. Korean J Intern Med 2005;20:26-32.
3. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004;110:2168-2174.
4. Gardner RS, Ozalp F, Murday AJ, et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003;24:1735-1743.
5. Freedman DS, Williamson DF, Gunter EW, et al. Relation of serum uric acid to mortality and ischemic heart disease: the NHANES I epidemiologic follow-up study. Am J Epidemiol 1995;141:637-644.
6. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000;283:2404-2410.
7. Niskanen LK, Laaksonen DE, Nyyssönen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004;164:1546-1551.
8. Verdecchia P, Schillaci G, Reboldi G, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: the PIUMA study. Hypertension 2000;36:1072-1078.
9. Mazza A, Pessina AC, Pavei A, et al. Predictors of stroke mortality in elderly people from the general population: the cardiovascular study in the elderly. Eur J Epidemiol 2001;17:1097-1104.
10. Weir CJ, Muir SW, Walters MR, et al. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003;34:1951-1956.
11. Bos MJ, Koudstaal PJ, Hofman A, et al. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 2006;37:1503-1507.
12. Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003;107:1991-1997.
13. Nieminen MS, Böhm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
15. Leyva F, Chua TP, Anker SD, et al. Uric acid in chronic heart failure: a measure of the anaerobic threshold. Metabolism 1998;47:1156-1159.
16. Leyva F, Anker S, Swan JW, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997;18:858-865.
17. Doehner W, von Haehling S, Anker SD. Uric acid as a prognostic marker in acute heart failure: new expectations from an old molecule. Eur J Heart Fail 2007;9:437-439.
18. Sakai H, Tsutamoto T, Tsutsui T, et al. Serum level of uric acid, partly secreted from the failing heart, is a prognostic marker in patients with congestive heart failure. Circ J 2006;70:1006-1011.
19. Cappola TP, Kass DA, Nelson GS, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001;104:2407-2411.
20. Cingolani HE, Plastino JA, Escudero EM, et al. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J Card Fail 2006;12:491-498.
21. Struthers AD, Donnan PT, Lindsay P, et al. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002;87:229-234.
22. Pascual-Figal DA, Hurtado-Martínez JA, Redondo B, et al. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail 2007;9:518-524.
23. Landmesser U, Spiekermann S, Dikalov S, et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002;106:3073-3078.
24. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-1283.
25. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1587-1593.
26. Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006;47:91-97.